Drugs / ABBV-438
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07409246 | Feb 2026 → Nov 2031 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-438 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07409246 ↗ |
| Route | Intravenous | “Intravenous (IV)” NCT07409246 ↗ |